Accessibility Help | Sitemap | Contact Us | Customer Support CALL +27 11 315 0445
South Africa Change Country
Home  |  Conditions  |  Products  |  Clinical Evidence  |  Education & Training  |  For Patients  |  Customer Support
You are here: Home > Products > Negative Pressure Technology Platform > V.A.C. Therapy > V.A.C. Therapy System Fact Sheet

V.A.C. Therapy System Fact Sheet


The KCI proprietary V.A.C.® Therapy System has revolutionised the way in which carers treat the most serious, complex wounds. V.A.C. Therapy uses an open-cell polymer foam dressing that is conformed to the wound bed. When sealed and placed under negative (vacuum) pressure, the system creates a unique wound healing environment that has been shown to promote the wound healing process, reduce oedema, prepare the wound bed for closure, promote the formation of granulation tissue and remove infectious materials.

Mechanisms of Action close up
V.A.C. Therapy System Illustration

3 McNulty A, Schmidt M, Feeley T, Kieswetter K. Effects of negative pressure wound therapy on fibroblast viability, chemotactic signaling, and proliferation in a provisional wound (fibrin) matrix. Wound Repair and Regeneration 2007; 15(6): 838-846.


In 1996, KCI introduced this innovative approach to the treatment of serious, complex wounds through the use of sub-atmospheric or negative pressure. Known today as “negative pressure wound therapy” (NPWT), KCI’s proprietary Vacuum Assisted Closure®, or V.A.C.® Therapy System has revolutionised the advanced wound care market and today remains the most clinically proven alternative for the treatment of complex, hard-to-heal wounds.

Product Portfolio


InfoVAC & ActiV.A.C.



The InfoV.A.C.® System  is a wound healing therapy system designed  for patients in the acute care setting.
The ActiV.A.C.® System  is designed for ambulatory patients and is used primarily in the home care setting.






The ABThera™ Open Abdomen Negative Pressure Therapy System addresses patient quality of life through an easy-to-use system designed to assist surgeons in the management and treatment of “open abdomen” and to help achieve primary fascial closure.

Research and Development (R&D)

KCI continues to invest in innovation with an ongoing commitment to research and development aimed at improving patient outcomes while reducing the overall cost of care. In 2008, KCI invested more than $76 million in its R&D efforts, which are led by approximately 240 clinical research and development professionals.

Clinical Distinction

V.A.C.® Therapy is recognised as a significant, clinically proven advancement in wound care that promotes active wound healing at the cellular level using three vital V.A.C. Therapy components:

  • The proprietary V.A.C.® GranuFoam™ Dressing means the difference between healing and simply draining a wound. GranuFoam Dressings provide increased metabolic activity and evenly distributes vacuum pressure at the wound surface, creating the angiogenesis and cell proliferation necessary for wound healing. Gauze-based negative pressure wound therapy devices only drain the wound. The technology of GranuFoam Dressings also allows the dressing to adapt to the contours of deep or unevenly shaped wounds.
  • The technology of SensaT.R.A.C.™ Dressings regulates pressure at the wound site to ensure patients receive the prescribed amount of negative pressure for optimal healing.
  • The V.A.C.® Therapy unit uses sophisticated software algorithms to provide intermittent and continuous negative pressure to the wound.

V.A.C. Therapy at a Glance

 Wounds Treated 8 million worldwide*
Usage Growth Rate 486 percent by prescribing physicians
Units Manufactured 42,000
Key Relationships Globally 21,000 hospitals and skilled nursing facilities
11,000 home health agencies
Caregivers Trained (Continuing Education) Accredited training for caregivers in all care settings
Customer Support 1,000+ member clinical sales team
24x7x365 Customer and Patient Support

*As of 12/31/13 KCI data on file

Clinical Study Support

KCI’s V.A.C. Therapy System enjoys an unprecedented body of clinical evidence that demonstrates clinical efficacy and cost-effectiveness, with:

  • 41 Randomised Controlled Trials (RCTs)
  • More than 918 Peer Reviewed Articles
  • More than 931 Abstracts
  • 71 Medical Text Book Citations

For more information, contact:

Kinetic Concepts, Inc.
Media Relations: for journalists only.

This Web page contains information about products which may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use.

Updated: 12 May 2014

  • Share on
  • Share on Twitter
  • Visit our YouTube page

Important Message for Patients

Legal Notice | Privacy Policy | Contact Us

Copyright © 1998 – 2013 KCI Licensing, Inc All Rights Reserved.   DSL# 09-03-193.ZA
The information included in this Web site has been prepared for and is intended for viewing exclusively within South Africa. This Web site contains information about products which may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications and restriction in different countries.